About

Overview

We are a research and clinical development biopharmaceutical company focused on developing protease therapeutics to address unmet medical needs in disorders of the complement system.

Proteases are natural regulators of this biological system. We engineer proteases to create improved or novel molecules to treat diseases that result from dysregulation of the complement cascade.

Our complement pipeline consists of CB 2782-PEG, preclinical complement component 3 degrader program for geographic atrophy in dry age-related macular degeneration, an improved Complement Factor I protease, CB 4332, for subcutaneous or intravitreal therapy to restore complement homeostasis in diseases of overactive complement or CFI deficiencies, and proteases from our ProTUNE™ C3b/C4b degrader and ImmunoTUNE™ C3a/C5a degrader platforms designed to target specific disorders of the complement or inflammatory pathways. Historically, we also used our protein engineering platform to develop potential therapies for coagulation disorders, including marzeptacog alfa (activated) (“MarzAA”), a SQ administered next-generation engineered coagulation Factor VIIa for the treatment of episodic bleeding and prophylaxis in subjects with rare bleeding disorders, and dalcinonacog alfa, a next-generation SQ FIX, both of which has shown sustained efficacy and safety in mid-stage clinical trials.

Management Team

We have assembled an experienced leadership team including world-class scientists, advisors, and collaborators. We have established, and continue to expand, a robust intellectual property position to advance and protect our business objectives.

Nassim Usman, Ph.D.

President and Chief Executive Officer

Grant Blouse, Ph.D.

Chief Scientific Officer

Tom Knudsen, DVM, Ph.D.

Senior Vice President, Corporate Development

Seline Miller, CPA

Senior Vice President, Finance

Interim Chief Financial Officer & Interim Principal Accounting Officer

Board

We have assembled an experienced leadership team including world-class scientists, advisors, and collaborators. We have established, and continue to expand, a robust intellectual property position to advance and protect our business objectives.

Augustine Lawlor, Chairman of the Board

Managing Director, HealthCare Ventures LLC

Errol B. De Souza, Ph.D.

Executive Chairman, Bionomics Ltd.

Andrea Hunt

Chair of G&N Committee, Member of Board of Directors, Catalyst Biosciences, Inc.

Jeanne Jew

Chief Business Officer, ALX Oncology

Geoffrey Ling, Ph.D.

Professor of Neurology and Attending Physician, Neuro Critical Care, Johns Hopkins Hospital

Sharon Tetlow

Managing Partner, Portrero Hill Advisors

Nassim Usman, Ph.D.

President and Chief Executive Officer, Catalyst Biosciences, Inc.

Eddie Williams

Member of Board of Directors, Catalyst Biosciences, Inc.

X